A Study of ASP3082 in Adults With Advanced Solid Tumors
← catalyst calendarNCT05382559 · readout in 865 d
Sponsored by Astellas Pharma Inc (industry) · 4503.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
681estimated
Sites
66
Countries
China, France, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-08 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: Setidegrasib — also filed as ASP3082
- Drug: Cetuximab
- Drug: Leucovorin
- Drug: Oxaliplatin
- Drug: Fluorouracil
- Drug: Irinotecan
- Drug: Nanoparticle albumin-bound-paclitaxel
- Drug: Gemcitabine
- Drug: Docetaxel
- Drug: Pembrolizumab
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Liposomal Irinotecan
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLTs)
measured Up to 28 Days
Number of Participants with Adverse Events (AEs)
measured Up to 48 months
Number of Participants with Serious Adverse Events (SAEs)
measured Up to 48 months
Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
measured Up to 48 months
Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
measured Up to 48 months
Number of Participants with vital sign abnormalities and/or adverse events (AEs)
measured Up to 48 months
Number of Participants with physical exam abnormalities and/or adverse events
measured Up to 48 months
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status
measured Up to 48 months
Publications
- PMID 41879829 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4503.T's whole pipeline · Catalyst calendar · Every registered study · What changed